Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency

DSpace/Manakin Repository

Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency

Citable link to this page

 

 
Title: Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency
Author: James, Andra H; Konkle, Barbara A; Bauer, Kenneth Alan

Note: Order does not necessarily reflect citation order of authors.

Citation: James, Andra H, Barbara A Konkle, and Kenneth A Bauer. 2013. Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency. International Journal of Women's Health 5: 233-241.
Full Text & Related Files:
Abstract: Objective: The aims of the study reported here were to provide data from six pregnant subjects who were enrolled in a clinical trial of antithrombin (AT) concentrate, discuss other published case series and case reports, and provide general guidance for the use of AT concentrate for inherited AT deficiency in pregnancy. Methods: In the late 1980s, 31 AT-deficient subjects were enrolled in a prospective treatment trial of the plasma-derived AT concentrate Thrombate III®. Herein, newly available treatment data about the six pregnant subjects in the trial is tabulated and summarized. Results: All six experienced venous thromboembolism (VTE) during pregnancy, were dosed according to a weight-based protocol, and were treated concomitantly with anticoagulation. Loading doses of AT concentrate of 54–62 units/kg were followed by maintenance doses of 50%–100% of the loading dose for 3–10 days. At the time of labor, loading doses of 46–50 units/kg were followed by maintenance doses of 50%–75% of the loading dose for 5–7 days. None of the six experienced recurrent thrombosis while receiving treatment with AT concentrate. Conclusion: Currently we suggest that women with AT deficiency who are pregnant or postpartum and have a personal history of VTE or current VTE receive AT concentrates.
Published Version: doi:10.2147/IJWH.S43190
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647601/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:11177950
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters